Caplin Point Labs acquires 10 ANDAs, targets $473M US market
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
The facility will manufacture tablets, capsules, and injections for the oncology segment
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
Subscribe To Our Newsletter & Stay Updated